 |
|
|
| |
Patient-Reported Outcomes Among Patients With Chronic Hepatitis Delta Treated With Bulevirtide 2 mg: A Long-Term Analysis of the Phase 3 MYR301 Trial at 144 Weeks
|
| |
| |
AASLD Nov 15-19, 2024 San Diego, CA
Rawi Hazzan1,2, Marvin Rock3, Odelia Tassa-Liani4, Yonatan Green4, Clara Weil5, Moshe Hoshen5, Sivan Gazit5, Chong Kim3
1Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel; 2Maccabi Healthcare Services, Tel Aviv, Israel; 3HEOR-Global Value and Access, Gilead Sciences, Inc., Foster City, CA, USA; 4Gilead Sciences Israel, Ltd., Hod Hasharon, Israel; 5Maccabi Research and Innovation Center, Maccabi Healthcare Services, Tel Aviv, Israel
|
| |
|
|
|
|
|
